HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sundt, T.M. Articles by Schaff, H.V. Search for Related Content PubMed PubMed Citation Articles by Sundt, T.M. Articles by Schaff, H.V. Related Collections Valve disease

J Thorac Cardiovasc Surg 2005;129:1024-1031
© 2005 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease

Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?

Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn

Read at the Thirtieth Annual Meeting of The Western Thoracic Surgical Association, Maui, Hawaii, June 23–26, 2004.

Received for publication June 21, 2004; revisions received November 18, 2004; accepted for publication November 23, 2004.

^_* Address for reprints: Thoralf M. Sundt III, MD, Division of Cardiovascular Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (E-mail: sundt.thoralf{at}mayo.edu).

OBJECTIVES: Freedom from anticoagulation is the principal advantage of bioprosthesis; however, the American Heart Association/American College of Cardiology and the American College of Chest Physicians guidelines recommend early anticoagulation with heparin, followed by warfarin for 3 months after bioprosthetic aortic valve replacement. We examined neurologic events within 90 days of bioprosthetic aortic valve replacement at our institution.

METHODS: Between 1993 and 2000, 1151 patients underwent bioprosthetic aortic valve replacement with (641) or without (510) associated coronary artery bypass. By surgeon preference, 624 had early postoperative anticoagulation (AC+) and 527 did not (AC–). In the AC– group, 410 patients (78%) received antiplatelet therapy. Groups were similar with respect to gender (female, 36% AC+ vs 40% AC–, P = .21), hypertension (64% AC+ vs 61%, P = .27), and prior stroke (7.6% AC+ vs 8.5% AC–, P = .54). The AC+ group was slightly younger than the AC– group (median, 76 years vs 78 years, P = .006).

RESULTS: Operative mortality was 4.1% with 43 (3.7%) cerebrovascular events within 90 days. Excluding 18 deficits apparent upon emergence from anesthesia, we found that postoperative cerebrovascular accident occurred in 2.4% of AC+ and 1.9% AC– patients. By multivariable analysis, the only predictor of operative mortality was hypertension (P < .0001). Postoperative cerebrovascular accident was unrelated to warfarin use (P = .32). The incidence of mediastinal bleeding requiring reexploration was similar (5.0% vs 7.4%), as were other bleeding complications in the first 90 days (1.1% vs 0.8%). No variables were predictive of bleeding by multivariate analysis.

CONCLUSIONS: Although these data do not address the role of antiplatelet agents, early anticoagulation with warfarin after bioprosthetic aortic valve replacement did not appear to protect against neurologic events.

This article has been cited by other articles:

				T. Al-Atassi, K. Lam, M. Forgie, M. Boodhwani, F. Rubens, P. Hendry, R. Masters, W. Goldstein, P. Bedard, T. Mesana, et al. Cerebral Microembolization After Bioprosthetic Aortic Valve Replacement: Comparison of Warfarin Plus Aspirin Versus Aspirin Only Circulation, September 11, 2012; 126(11_suppl_1): S239 - S244. [Abstract] [Full Text] [PDF]

				M. L. Brown, S. J. Park, T. M. Sundt, and H. V. Schaff Early thrombosis risk in patients with biologic valves in the aortic position J. Thorac. Cardiovasc. Surg., July 1, 2012; 144(1): 108 - 111. [Abstract] [Full Text] [PDF]

				M. I. Mydin, G. Dimitrakakis, J. Younis, J. Nowell, T. Athanasiou, and A. Kourliouros Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate? Interact CardioVasc Thorac Surg, July 1, 2012; 15(1): 109 - 114. [Abstract] [Full Text] [PDF]

				A. W. ElBardissi and L. H. Cohn Reply to the Editor J. Thorac. Cardiovasc. Surg., September 1, 2010; 140(3): 725 - 726. [Full Text] [PDF]

				A. W. ElBardissi, D. J. DiBardino, F. Y. Chen, M. H. Yamashita, and L. H. Cohn Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J. Thorac. Cardiovasc. Surg., May 1, 2010; 139(5): 1137 - 1145. [Abstract] [Full Text] [PDF]

				J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A. M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery Eur J Cardiothorac Surg, July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]

				M. Brueck, W. Kramer, P. Vogt, N. Steinert, P. Roth, G. Gorlach, M. Schonburg, and M. C. Heidt Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors Eur J Cardiothorac Surg, July 1, 2007; 32(1): 108 - 112. [Abstract] [Full Text] [PDF]

				F. di Marco, S. Grendene, G. Feltrin, D. Meneghetti, and G. Gerosa Antiplatelet therapy in patients receiving aortic bioprostheses: A report of clinical and instrumental safety J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1597 - 1603. [Abstract] [Full Text] [PDF]

				A. Colli, J.-P. Verhoye, A. Leguerrier, and T. Gherli Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue Eur J Cardiothorac Surg, April 1, 2007; 31(4): 573 - 577. [Abstract] [Full Text] [PDF]

				J. Nowell, E. Wilton, H. Markus, and M. Jahangiri Antithrombotic therapy following bioprosthetic aortic valve replacement Eur J Cardiothorac Surg, April 1, 2007; 31(4): 578 - 585. [Abstract] [Full Text] [PDF]

				W.R. E. Jamieson, S. D. Moffatt-Bruce, P. Skarsgard, M. A. Hadi, J. Ye, G. J. Fradet, J. G. Abel, M. T. Janusz, A. Cheung, and E. Germann Early Antithrombotic Therapy for Aortic Valve Bioprostheses: Is There an Indication for Routine Use? Ann. Thorac. Surg., February 1, 2007; 83(2): 549 - 557. [Abstract] [Full Text] [PDF]

				M. El-Husseiny, K. Salhiyyah, S. G. Raja, and J. Dunning Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement? Interact CardioVasc Thorac Surg, October 1, 2006; 5(5): 616 - 623. [Abstract] [Full Text] [PDF]

				F. di Marco, M. Giordan, and G. Gerosa Early antithrombotic therapy after aortic valve replacement with tissue valves: When the practice diverges from the guidelines J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1223 - 1223. [Full Text] [PDF]

				F. di Marco, G. Meneghetti, and G. Gerosa Early anticoagulation after aortic valve replacement with bioprostheses: Time to abandon it? J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1482 - 1483. [Full Text] [PDF]